Elsevier

Respiratory Medicine

Volume 96, Issue 8, August 2002, Pages 625-631
Respiratory Medicine

Regular Article
HPA-axis effects of nebulised fluticasone propionate compared with oral prednisolone in childhood asthma

https://doi.org/10.1053/rmed.2002.1323Get rights and content
Under an Elsevier user license
open archive

Abstract

The aim of this study was to compare the effect of 7 days nebulised fluticasone propionate (FP) with oral prednisolone on 24-h urinary-free cortisol excretion, systemic exposure and safety. This was a randomised, double-blind, double-dummy, two-way crossover study. Thirty-one children (19 male, 12 female, mean age 8 years) with stable asthma were randomly assigned to 7 days treatment with either FP NebulesTM (2×0.5 mg/2 ml bd) or prednisolone tablets once daily (2 mg/kg/day for 4 days [maximum 40 mg] followed by 1 mg/kg/day or half the original dose for 3 days [maximum 20 mg]). After a 2–4 week washout period, patients received the second treatment for 7 days, followed by a 2-week follow-up visit. The primary outcome measure was 24-h urinary-free cortisol concentrations corrected for creatinine. Nebulised FP (1 mg bd) had significantly less effect on 24-h urinary-free cortisol excretion than oral prednisolone (8.9 ng/ml for FP and 5.0 ng/ml for prednisolone, P=0.001). Systemic exposure to FP was also low. In conclusion, FP NebulesTM had significantly less effect on hypothalamic–pituitary–adrenal axis function than oral prednisolone in asthmatic children when used at doses recommended for the treatment of an acute exacerbation of asthma.

Keywords

fluticasone propionate
NebulesTM
prednisolone
asthma
urinary cortisol.

Cited by (0)

f1

Correspondence should be addressed to: Professor John Price, Department of Child Health, King's College Hospital, Denmark Hill, London, SE5 9RS, U.K. Fax: +44-207-346-3657; E-mail: [email protected]